Login to Your Account

Sooner-than-Expected FDA Nod for Amgen's Bone Drug Prolia

By Jennifer Boggs

Wednesday, June 2, 2010
Nearly two months ahead of its July 25 PDUFA date, Amgen Inc.'s Prolia (denosumab) gained FDA approval in postmenopausal women with osteoporosis who are at high risk for fractures, and that earlier-than-expected win could bode well as the Thousand Oaks, Calif.-based firm seeks to expand denosumab in other indications. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription